Governance & Boards

WP1 for management and coordination: WP1 implements the transversal activities of project coordination of over 50 partners, the five WPs, and Advisory Bodies as well as activities for external project communication, dissemination and cooperation. All dissemination activities and events, managed centrally by WP1 in close collaboration with the other WPs, enable a close interaction of EP PerMed with the scientific community, policy makers, R&I funding organisations, European programmes, public and private sectorsand other stakeholders. WP1 further coordinates EP PerMed’s strategic planning, such as supplementing and updating the Strategic Research and Innovation Agenda for Personalised Medicine (SRIA for PM, 2023), preparing Annual Work Programmes (AWP), identifying future developments, and exploring synergies with other initiatives. Also, the coordinator and WP1 are the main contact for the European Commission.

Main contributors: DLR, ANR, VLO-EWI, IACS, TLS, CSO-MOH, ISCIII, FTELE, It-MoH, VINNOVA, BMBWF-AT, MUR

WP2 for PM research-related funding and support: WP2 implements joint funding activities, especially the seven annual Joint Transnational Calls (JTC2024-2030), but also other foreseen calls, e.g. Network Calls and Research Technology and Innovation Calls (RITC), in all areas of PM-related research. The thematic focus of funding activities is being developed along the recommendation of the SRIA, other recent developments related to PM and indicated in the partnership’s AWP. Particularly, with JTC and RITC, EP PerMed aims to establish and fund research and innovation collaborative projects of different sizes and durations on priority areas of common interest and based on needs identified through WP3 and WP4 mapping activities. The different funding and supporting activities will enable scientists, clinicians, and innovators to build an effective transnational collaboration on common interdisciplinary consortia, and also contribute to strengthening the collaboration between different types of sectors and stakeholder.

Main contributors: ANR, BMBWF-AT, DLR, ISCIII, Zon, EITH, VLO-EWI, VINNOVA, RCN, It-MoH, CSO-MOH, FRS-FNRS

WP3 for accelerating PM development, innovation, and absorption – maximising impact: WP3 accelerates innovation, absorption, and implementation of PM in collaboration with the other WPs, in particular WP4. The EP PerMed Radar analyses the innovation potential of funded projects and builds on the work within WP2, WP4, and WP5 to develop insights of needs and options for development and innovation. The analysis also builds on input from dialogues with regions, national and international stakeholders. The EP PerMed Accelerator covers three parts – offers, connect and act. (I) Offers include information on e.g. available tools, calls, resources, programmes, infrastructures and events to further develop projects outcomes and PM approaches. (II) Connect facilitates connections of needs and offers between various partners for new collaborations to support PM innovations. (III) Act proposes actions, activities and tools according to the identified needs.

Main contributors: VLO-EWI, DLR, ANR, TLS, ISCIII, FTELE, EITH, VINNOVA, BBMRI-ERIC, IACS, BIOEF, InnoSuisse

WP4 for the implementation of PM in public healthcare: WP4 communicates progress and knowledge within all PM areas which are relevant for PM implementation into healthcare systems, and which demonstrate the value of PM in terms of quality of care, quality of life, cost-effectiveness, and sustainability. This includes knowledge and information about new therapies, biomarkers, diagnostics, devices, preventive measures, and processes, as well as insights relating to ethical, legal, societal, and political aspects. Full implementation of PM in healthcare will require different levels of developments in the diverse healthcare systems and this will take time and effort. There is therefore a need to communicate and discuss at a more overall level the opportunities PM provides. WP4 will keep such discussions alive through, e.g. dedicated panels, meetings, and networking activities. A broad set of EP PerMed tools will be developed and available to reach the WP4 objectives, e.g., best practice examples, workshops/conferences, white papers, networking activities, pilot- and demonstration projects. Some of the actions will be in cooperation with ICPerMed and other PM-related initiatives.

Main contributors: IACS, It-MoH, CSO-MOH, SFI, DLR, BIOEF, EITH, RT, DPTO-Salud, TUBITAK

WP5 for International, Transnational, Interregional and Overarching Cooperation: WP5 aims to leverage and reinforce the collaboration with stakeholders at regional, international, transnational and interregional level, building on the achievements of the International Consortium for Personalised Medicine, ICPerMed and releated initiatives and projects. Another collaboration is being built with regional and national research and innovation communities, which are proven to ease the access of PM innovation into clinical and healthcare settings and accelerating people’s access to personalised intervention. Additionally, WP5 engages and involves citizens and medical societies, and closely connects to research and innovation infrastructures on European and national level. It furthermore provides training and support on PM-specific ethical, legal, data protection, data sharing and reuse as well as social and economic and value aspects.

Main contributors: TLS, DLR, ANR, BMBWF-AT, Zon, FRRB, FTELE, DPTO-Salud, BIOEF, CFN, DS-CAT, RT, SMWK, IACS, BBMRI-ERIC, ISCIII, EITH, AICIB